TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32881403

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5490

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5490

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI) with increased WC
Number of subjects: 5490
Study: 35975564

Group type: EXPERIMENTAL
Intervention: Ginseng (1 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 33819509

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG administered for 3 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus rhamnosus GG
Number of subjects: 28

Group type: COMPARATOR
Intervention: Patients with APS‐1
Number of subjects: 28
Study: 32120316

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (two synbiotic capsules daily for 2 months)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 42
Study: 35220124

Group type: EXPERIMENTAL
Intervention: QAMS method for quantifying aflatoxins and their precursors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QAMS method
Number of subjects: 0
Study: 33269429

Group type: EXPERIMENTAL
Intervention: MGB/OAGB
Number of subjects: 58

Group type: COMPARATOR
Intervention: LSG
Number of subjects: 58
Study: 35090399

Group type: EXPERIMENTAL
Intervention: Wrist HBPM device
Number of subjects: 100

Group type: COMPARATOR
Intervention: Arm HBPM device
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: More accurate device
Number of subjects: 100
Study: 33818939

Group type: EXPERIMENTAL
Intervention: Hydrophilic nutrients (BESTFertil dietary supplement, 4 capsules per day)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lipophilic nutrients (dietary supplement 'BrudiPlus', 3 capsules per day)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Hydrophilic nutrients
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Lipophilic nutrients
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Hydrophilic and lipophilic nutrients
Number of subjects: 160
Study: 34020099

Group type: EXPERIMENTAL
Intervention: Rx for Success (RxS) mobile app
Number of subjects: 252

Group type: COMPARATOR
Intervention: Control (children's book modeling alternatives to screen time)
Number of subjects: 252
Study: 32087922

Group type: EXPERIMENTAL
Intervention: T. orientalis Ikeda type infection
Number of subjects: 10
Study: 34478166

Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg once daily) plus Pembrolizumab (200 mg every 3 weeks) in cohort 1
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Niraparib (200 mg once daily) plus Pembrolizumab (200 mg every 3 weeks) in cohort 2
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Niraparib plus Pembrolizumab in cohort 1
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Niraparib plus Pembrolizumab in cohort 2
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Niraparib plus Pembrolizumab in cohorts 1 and 2
Number of subjects: 38
Study: 34016868

Group type: EXPERIMENTAL
Intervention: Light rolling cotton swab touch
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lidocaine 4% topical solution
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vulvalgesiometer
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Verbal Pain Scale
Number of subjects: 16
Study: 36342151

Group type: EXPERIMENTAL
Intervention: Double sequential external defibrillation (DSED)
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Vector-change (VC) defibrillation
Number of subjects: 405

Group type: COMPARATOR
Intervention: Standard defibrillation
Number of subjects: 405
Study: 34496278

Group type: EXPERIMENTAL
Intervention: 12‐weeks of supervised, treadmill walking exercise training
Number of subjects: 11

Group type: COMPARATOR
Intervention: 12‐weeks of low‐intensity resistive exercise (active control condition)
Number of subjects: 11
Study: 32921767

Group type: EXPERIMENTAL
Intervention: Lertal® (nutraceutical)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 0
Study: 36347569

Group type: EXPERIMENTAL
Intervention: Meal M2 (rice cooked with coconut oil)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meal M1 (rice)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meal M3 (rice cooked in coconut oil with lentils)
Number of subjects: 20
Study: 34426466

Group type: EXPERIMENTAL
Intervention: Standard diagnostic examination (SDE) plus a CAD‐score
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard diagnostic examination (SDE) according to current guidelines
Number of subjects: 2000
Study: 35805371

Group type: EXPERIMENTAL
Intervention: Crockery Set
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Utensil Set
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Both tools
Number of subjects: 31
Study: 33464683

Group type: EXPERIMENTAL
Intervention: Strict low FODMAP diet (LFD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Modified low FODMAP diet (LFD)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Traditional dietary advice (TDA)
Number of subjects: 101
Study: 35507334

Group type: EXPERIMENTAL
Intervention: Nomacopan, 90 mg subcutaneously on day 1 and 30 mg subcutaneously daily until day 42
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nomacopan
Number of subjects: 9
Study: 34626008

Group type: EXPERIMENTAL
Intervention: Low-dose rhEPO (40 IU/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rhEPO micro-doses (900 IU)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Washout phase after rhEPO administration
Number of subjects: 20
Study: 33146720

Group type: EXPERIMENTAL
Intervention: Matrix‐M‐adjuvanted qNIV
Number of subjects: 1375

Group type: COMPARATOR
Intervention: IIV3‐HD
Number of subjects: 1375

Group type: COMPARATOR
Intervention: RIV4
Number of subjects: 1375

Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 1375
Study: 36001436

Group type: COMPARATOR
Intervention: Alcohol administration (oral and intravenous, variable and fixed doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individuals with AUD
Number of subjects: 0
Study: 33264662

Group type: EXPERIMENTAL
Intervention: Trigeminal nerve stimulation (TNS) for 4 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 62
Study: 35708758

Group type: EXPERIMENTAL
Intervention: (1 → 3)‐β‐d‐Glucan (BDG) guidance
Number of subjects: 339

Group type: COMPARATOR
Intervention: Control group (targeted antifungal therapy driven by culture results)
Number of subjects: 339
Study: 33431819

Group type: EXPERIMENTAL
Intervention: Arachidonoylcyclopropylamide (ACPA) at IC50 of 1.39 × 10‐12 M
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACPA-PCL nanoparticle system
Number of subjects: 0

Group type: COMPARATOR
Intervention: CB1 antagonist AM281
Number of subjects: 0
Study: 35143340

Group type: EXPERIMENTAL
Intervention: Postpartum yoga practice (60 minutes, 2 days a week for 8 weeks)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Control group (no yoga practice)
Number of subjects: 124
Study: 33754924

Group type: EXPERIMENTAL
Intervention: Dacomitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Osimertinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Afatinib
Number of subjects: 0
Study: 32240480

Group type: EXPERIMENTAL
Intervention: KiVa Bullying Prevention Program
Number of subjects: 3214

Group type: COMPARATOR
Intervention: Usual school provision (waitlist control)
Number of subjects: 3214
Study: 32530339

Group type: EXPERIMENTAL
Intervention: Synbiotic (five drops/day)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU daily)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (routine treatments only)
Number of subjects: 81
Study: 32948108

Group type: EXPERIMENTAL
Intervention: Analogy learning
Number of subjects: 40

Group type: COMPARATOR
Intervention: Explicit learning
Number of subjects: 40
Study: 32546256

Group type: EXPERIMENTAL
Intervention: IMPROVEjob intervention
Number of subjects: 56

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 56
Study: 35389961

Group type: EXPERIMENTAL
Intervention: High-dose Levothyroxine
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: High-dose Methylprednisolone
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Combo (High-dose Levothyroxine + High-dose Methylprednisolone)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control (No hormonal therapy)
Number of subjects: 199
Study: 32997088

Group type: EXPERIMENTAL
Intervention: GC (glaze on compression side)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GT (glaze on tensile side)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GTC (glaze on both sides)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: GTC-A (glaze on both sides, aged)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no glazing)
Number of subjects: 80
Study: 33875324

Group type: EXPERIMENTAL
Intervention: Walking Training (WT), two sessions/week, 15 cycles of two minutes walking at pain threshold intensity interspersed by two minutes of upright rest
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Walking Training (WT)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (CO), two sessions/week, 30 minutes of stretching
Number of subjects: 32
Study: 35490603

Group type: EXPERIMENTAL
Intervention: 10 mL drain removal
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 20 mL drain removal
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: 30 mL drain removal
Number of subjects: 187
Study: 34088920

Group type: COMPARATOR
Intervention: Regular calcium + 5 x 10^8 CFU/day L. casei CRL 431 (Casei)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Regular calcium + 5 x 10^8 CFU/day Lactobacillus reuteri DSM 17938 (Reuteri)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Low-lactose milk fortified with low levels of calcium (LC)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Regular levels of calcium (RC)
Number of subjects: 238
Study: 35209942

Group type: EXPERIMENTAL
Intervention: 30 g/day probiotic cheese
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-salt and low-fat cheese without any added probiotic
Number of subjects: 40
Study: 32713421

Group type: EXPERIMENTAL
Intervention: CPAP therapy after 6 weeks
Number of subjects: 7

Group type: COMPARATOR
Intervention: CPAP titration
Number of subjects: 7
Study: 34217036

Group type: EXPERIMENTAL
Intervention: CBT + FE
Number of subjects: 25

Group type: COMPARATOR
Intervention: CBT
Number of subjects: 25
Study: 32555037

Group type: EXPERIMENTAL
Intervention: Reverse Shoulder Arthroplasty
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plate Fixation
Number of subjects: 0
Study: 36102822

Group type: EXPERIMENTAL
Intervention: Methylnaltrexone
Number of subjects: 3718

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3718
Study: 33966526

Group type: EXPERIMENTAL
Intervention: Telephone support programme with telemonitoring
Number of subjects: 2607

Group type: COMPARATOR
Intervention: Self-directed control arm
Number of subjects: 2607
Study: 36089010

Group type: EXPERIMENTAL
Intervention: AUHII (Urban Heat Island Intensity)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: △AUHI (Change in Urban Heat Island Intensity)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: CTRUMR (Urban minus Rural)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: CTROMR (Observation minus Reanalysis)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Cooling impact observed in some cities
Number of subjects: 86
Study: 34309665

Group type: COMPARATOR
Intervention: Standard arm (bevacizumab administered on the same day as chemotherapy)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Experimental arm (bevacizumab administered 4 days before chemotherapy)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Standard arm
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Experimental arm
Number of subjects: 230
Study: 34464485

Group type: COMPARATOR
Intervention: Active frontopolar tDCS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham frontopolar tDCS
Number of subjects: 24
Study: 33189161

Group type: EXPERIMENTAL
Intervention: SNG001 (6 MIU) inhaled daily for 14 days
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo inhaled daily for 14 days
Number of subjects: 101
Study: 34134824

Group type: EXPERIMENTAL
Intervention: Critical Body Checking (CBC)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Neutral Body Checking (NBC)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Non-Body Critical Checking (NBCC)
Number of subjects: 142
Study: 36217132

Group type: EXPERIMENTAL
Intervention: Qualitative exploration of perceived barriers to exclusive breastfeeding
Number of subjects: 30
Study: 34642002

Group type: EXPERIMENTAL
Intervention: Progressive exercise (PRO)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: General exercise (GEN)
Number of subjects: 41
Study: 32375684

Group type: EXPERIMENTAL
Intervention: Strengthened health management committees and community mobilisation through women's groups
Number of subjects: 13721

Group type: COMPARATOR
Intervention: Control clusters (22 clusters)
Number of subjects: 13721
Study: 34863145

Group type: EXPERIMENTAL
Intervention: Nurse-led sexual rehabilitation intervention
Number of subjects: 220

Group type: COMPARATOR
Intervention: Optimal care as usual (CAU)
Number of subjects: 220
Study: 35998039

Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (1000 mg) + Pterostilbene (200 mg)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 33871071

Group type: EXPERIMENTAL
Intervention: Combination of topical and oral glutathione
Number of subjects: 46

Group type: COMPARATOR
Intervention: Topical glutathione
Number of subjects: 46

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 46
Study: 34763847

Group type: EXPERIMENTAL
Intervention: Unconscious exposure to spiders
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Visible exposure to spiders
Number of subjects: 98

Group type: COMPARATOR
Intervention: Unconscious exposure to flowers (control)
Number of subjects: 98
Study: 34247632

Group type: COMPARATOR
Intervention: Standard prednisolone (1 mg/kg/day)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Reduced prednisolone (0.5 mg/kg/day) and alfacalcidol (0.5 μg/day)
Number of subjects: 96
Study: 33171595

Group type: EXPERIMENTAL
Intervention: Probiotic plus biotin treatment
Number of subjects: 82

Group type: COMPARATOR
Intervention: Biotin plus placebo
Number of subjects: 82
Study: 32000408

Group type: EXPERIMENTAL
Intervention: Fried frailty scale
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instrumental activities of daily living scale (IADL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventional treatment
Number of subjects: 0
Study: 32000590

Group type: EXPERIMENTAL
Intervention: Anticoagulation treatment for atrial fibrillation after intracerebral hemorrhage
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no anticoagulation)
Number of subjects: 0
Study: 32000787

Group type: EXPERIMENTAL
Intervention: Persistent pain in adolescents
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Self-efficacy as a mediator
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Future pain-management interventions
Number of subjects: 78
Study: 32000810

Group type: EXPERIMENTAL
Intervention: V934/V935 hTERT vaccination (prime-boost regimen with V935 and V934)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: V934/V935 hTERT vaccination
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: V934/V935 hTERT vaccination in prostate cancer patients
Number of subjects: 37
Study: 32000819

Group type: EXPERIMENTAL
Intervention: Multisession radiosurgery delivering 25 Gy in 5 daily fractions
Number of subjects: 0
Study: 32002194

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32002290

Group type: EXPERIMENTAL
Intervention: ADP-A2M4 T-cell therapy
Number of subjects: 0
Study: 32002540

Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Norepinephrine and Epinephrine (multivariate model)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Epinephrine and Norepinephrine
Number of subjects: 202
Study: 32002821

Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide and dexamethasone (D-Rd)
Number of subjects: 7
Study: 32002847

Group type: EXPERIMENTAL
Intervention: Stress myocardial blood flow (MBF) per-vessel
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Myocardial flow reserve (MFR)
Number of subjects: 231
Study: 32003099

Group type: EXPERIMENTAL
Intervention: Second-line insulin secretagogues (IS) or insulin
Number of subjects: 6217

Group type: COMPARATOR
Intervention: No IS and insulin
Number of subjects: 6217
Study: 32003749

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavioral internet-delivered treatment
Number of subjects: 214

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 214
Study: 32004245

Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP) activated ON at implant for patients with RV-to-LV delay less than 80 ms
Number of subjects: 248

Group type: COMPARATOR
Intervention: Multipoint pacing (MPP) OFF for patients with RV-to-LV delay at least 80 ms
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Multipoint pacing (MPP)
Number of subjects: 248
Study: 32004352

Group type: EXPERIMENTAL
Intervention: Next of Kin Participation in Care questionnaire (self-reported)
Number of subjects: 364
Study: 32004497

Group type: EXPERIMENTAL
Intervention: Total screen viewing time (≥3 h per day)
Number of subjects: 552

Group type: COMPARATOR
Intervention: Total screen viewing time (≤1 h per day)
Number of subjects: 552
Study: 32004554

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Emergency Department (ED) visits
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ICU admissions
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Hospital days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ICU days
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Annual costs for ICU admission
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Annual costs for inpatient care
Number of subjects: 300
Study: 32004908

Group type: EXPERIMENTAL
Intervention: One-step nucleic acid amplification (OSNA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pathological analysis
Number of subjects: 26
Study: 32005002

Group type: EXPERIMENTAL
Intervention: JAK2 V617F positive ET
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 36
Study: 32005112

Group type: EXPERIMENTAL
Intervention: Standardized questionnaires administered at three time points (t1, t2, t3)
Number of subjects: 2000
Study: 32005159

Group type: EXPERIMENTAL
Intervention: Rural GPs
Number of subjects: 211

Group type: COMPARATOR
Intervention: Urban GPs
Number of subjects: 211
Study: 32005181

Group type: EXPERIMENTAL
Intervention: 70-gene risk of recurrence signature (70-GS, MammaPrint)
Number of subjects: 358
Study: 32005333

Group type: EXPERIMENTAL
Intervention: Smartphone-delivered individual cognitive-behavioral therapy (CBT) for BDD
Number of subjects: 10
Study: 32005489

Group type: EXPERIMENTAL
Intervention: Deep Inspiration Breath-Hold (DIBH) technique
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: DIBH training and equipment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: DIBH compliance assessment
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: DIBH technique feasibility
Number of subjects: 33
Study: 32006121

Group type: EXPERIMENTAL
Intervention: Aortic root replacement by graft
Number of subjects: 19
Study: 32006348

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 783

Group type: COMPARATOR
Intervention: Observational comparison cohort (conventional synthetic DMARD, biologic DMARD, or apremilast)
Number of subjects: 783

Group type: EXPERIMENTAL
Intervention: All-tofacitinib comparison cohort
Number of subjects: 783
Study: 32006647

Group type: EXPERIMENTAL
Intervention: Toe brachial index (TBI) tertile 1
Number of subjects: 741
Study: 32006951

Group type: EXPERIMENTAL
Intervention: fMRI
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: MEG
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Combined MEG and fMRI
Number of subjects: 19
Study: 32007132

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 32007426

Group type: COMPARATOR
Intervention: Solifenacin oral suspension (pediatric equivalent doses 2.5-10 mg) for 12 weeks followed by a fixed dose ≥40-week treatment period.
Number of subjects: 0
Study: 32007598

Group type: EXPERIMENTAL
Intervention: Alflutinib (20 mg, 40 mg, 80 mg, 160 mg, or 240 mg once daily)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Alflutinib (40-240 mg)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Alflutinib
Number of subjects: 130
Study: 32008218

Group type: EXPERIMENTAL
Intervention: Antibiotics before chemotherapy
Number of subjects: 1446

Group type: EXPERIMENTAL
Intervention: Antibiotics during chemotherapy
Number of subjects: 1446

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 1446
Study: 32008915

Group type: EXPERIMENTAL
Intervention: Apnea-hypopnea index (AHI) ≥ 2
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: High CMR (CMR+)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Low CMR (CMR-)
Number of subjects: 114
Study: 32008981

Group type: EXPERIMENTAL
Intervention: Glutamate and GABA levels in UHR individuals
Number of subjects: 122

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 122
Study: 32009149

Group type: EXPERIMENTAL
Intervention: Veliparib with radiation followed by veliparib and temozolomide (TMZ)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Veliparib with radiation
Number of subjects: 66
Study: 32009165

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-velpatasvir for 12 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Opioid Agonist Therapy (OAT)
Number of subjects: 100
Study: 32009263

Group type: EXPERIMENTAL
Intervention: AdaptivCRT (aCRT) ON
Number of subjects: 1814

Group type: COMPARATOR
Intervention: Standard CRT
Number of subjects: 1814